Foliglurax

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Foliglurax
Foliglurax tautomer skeletal.svg
Clinical data
SynonymsDT-1687; PXT-002331; PXT-2331
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H23N3O3S
Molar mass421.515 g/mol g·mol−1
3D model (JSmol)

Foliglurax (developmental code names PXT-002331, DT-1687) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4) which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[1][2] As of July 2017, it is in phase II clinical trials.[1]

The other tautomeric form of foliglurax.

References[edit]

  1. ^ a b http://adisinsight.springer.com/drugs/800044176
  2. ^ Ellis, J. Michael; Fell, Matthew J. (2017). "Current approaches to the treatment of Parkinson's Disease". Bioorganic & Medicinal Chemistry Letters. doi:10.1016/j.bmcl.2017.07.075. ISSN 0960-894X. PMID 19043519.

External links[edit]